ProCE Banner Activity

Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC

Podcast Episodes

Audio podcast with expert insights on the current treatment landscape for first-line management of HER2-positive metastatic breast cancer considering the latest available evidence. 

Released: March 25, 2025

Expiration: March 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC. in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Smart Patients

ProCE Banner

Disclosure

Primary Author

Stephanie L. Graff, MD, FACP, FASCO: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech, Gilead, Lilly, Loxo, Menarini Stemline, Novartis, Pfizer, Seagen; researcher (paid to institution): AstraZeneca/Daiichi Sankyo, Daiichi Sankyo, Lilly, Novartis.

Laura Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Precede, Seagen; researcher: AstraZeneca, Genentech, Gilead, Lilly, Merck; other (travel support): Lilly.